Top 10 Cited Papers in 2021

In 2021, TIMI-authored papers received a total of 25,224 citations.  All-time citations at the end of 2021 exceeded 308,000, with an H-index of 271.

Top Papers Cited in 2021, Published Anytime

836 Citations – Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357.

466 Citations – Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722.

402 Citations – Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62.

391 Citations – SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39.

382 Citations – Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104.

271 Citations – Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97.doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.

237 Citations – Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4.

181 Citations – Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.

153 Citations – Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11.

150 Citations – Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.

Hot Papers Published in 2020, Cited in 2021

52 Citations – Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020 Apr 14;141(15):1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183. Epub 2020 Jan 27.

36 Citations – Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score Results From the FOURIER Trial. Circulation. 2020 Feb 25;141(8):616-623. doi: 10.1161/CIRCULATIONAHA.119.043805. Epub 2019 Nov 11.

35 Citations – The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y(12)Inhibitor in Patients After Percutaneous Coronary Intervention A Systematic Review and Meta-Analysis. Circulation. 2020 Aug 11;142(6):538-545. doi: 10.1161/CIRCULATIONAHA.120.046251. Epub 2020 Jun 19.

29 Citations – Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020 Nov 21;396(10263):1637-1643. doi: 10.1016/S0140-6736(20)32332-1. Epub 2020 Nov 10.

22 Citations – Use of Temporary Mechanical Circulatory Support for Management of Cardiogenic Shock Before and After the United Network for Organ Sharing Donor Heart Allocation System Changes. JAMA Cardiol. 2020 Jun 1;5(6):703-708. doi: 10.1001/jamacardio.2020.0692.

21 Citations – Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021 May 1;6(5):499-507. doi: 10.1001/jamacardio.2020.7585.

18 Citations – Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020 May;51(5):1546-1554. doi: 10.1161/STROKEAHA.119.027759. Epub 2020 Apr 21.

16 Citations – The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 2020 May 19;141(20):1600-1607. doi: 10.1161/CIRCULATIONAHA.120.046397. Epub 2020 Mar 29.

15 Citations – Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care. 2020 Feb;43(2):468-475. doi: 10.2337/dc19-1476. Epub 2019 Dec 16.

15 Citations – Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 Feb 1;5(2):202-207. doi: 10.1001/jamacardio.2019.4665.

TIMI Publications and Times Cited Over Time